Luis Lopez-Navas
Overview
Explore the profile of Luis Lopez-Navas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez-Navas L, Torrents S, Sanchez-Pernaute R, Vives J
Stem Cells Transl Med
. 2022 Jul;
11(8):805-813.
PMID: 35830540
The development of cell-, gene- and tissue engineering (CGT)-based therapies must adhere to strict pharmaceutical quality management standards, as for any other biological or small-molecule drug. However, early developments often...
2.
Munoz B, Lopez-Navas L, Gonzalez Bermejo M, Lomas Romero I, Montiel Aguilera M, Cuerva R, et al.
Platelets
. 2021 Jan;
33(1):98-109.
PMID: 33393414
Recent years have witnessed the introduction of expanded dermal fibroblasts for several cell therapy and tissue-engineering applications, including the treatment of facial scars and burns, representing a promising cell type...
3.
Fernandez-Munoz B, Rosell-Valle C, Ferrari D, Alba-Amador J, Montiel M, Campos-Cuerva R, et al.
Stem Cells Transl Med
. 2020 Jun;
9(9):1085-1101.
PMID: 32475061
Intraventricular hemorrhage is a common cause of morbidity and mortality in premature infants. The rupture of the germinal zone into the ventricles entails loss of neural stem cells and disturbs...
4.
Rico-Sanchez L, Garzon I, Gonzalez-Andrades M, Ruiz-Garcia A, Punzano M, Lizana-Moreno A, et al.
J Tissue Eng Regen Med
. 2019 Aug;
13(12):2142-2154.
PMID: 31373143
Blindness due to corneal diseases is a common pathology affecting up to 23 million individuals worldwide. The tissue-engineered anterior human cornea, which is currently being tested in a Phase I/II...
5.
Campos-Cuerva R, Fernandez-Munoz B, Farfan Lopez F, Pereira Arenas S, Santos-Gonzalez M, Lopez-Navas L, et al.
J Tissue Eng Regen Med
. 2019 Feb;
13(4):664-673.
PMID: 30793853
Blood loss remains a major concern during surgery and can increase the morbidity of the intervention. The use of topical haemostatic agents to overcome this issue therefore becomes necessary. Fibrin...